<p>Geode Capital Management LLC 在最近向證券交易委員會的披露中表示，在第二季度增持了 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免費報告) 的股份，增幅為 1.3%。該公司在本季度額外購買了 26,365 股後，持有 2,049,350 股該公司的股票。Geode Capital Management LLC 在最近一個季度末持有 Syndax Pharmaceuticals 約 2.38% 的股份，價值 19,195,000 美元。</p>
<p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<p>其他機構投資者最近也調整了對該公司的持股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度新購入了 Syndax Pharmaceuticals 的股份，價值 179,000 美元。XTX Topco Ltd 在第一季度購買了 Syndax Pharmaceuticals 的新頭寸，價值 783,000 美元。德意志銀行在第一季度將其在 Syndax Pharmaceuticals 的持股增加了 127.7%。德意志銀行目前持有 204,732 股該公司的股票，價值 2,516,000 美元，此前在上個季度額外購入了 114,828 股。Invesco Ltd. 在第一季度將其在 Syndax Pharmaceuticals 的持股增加了 49.7%。Invesco Ltd. 目前持有 76,848 股該公司的股票，價值 944,000 美元，此前在此期間額外購入了 25,524 股。最後，Aigen Investment Management LP 在第一季度新購入了價值約 297,000 美元的 Syndax Pharmaceuticals 的股份。</p>
<h2>Syndax Pharmaceuticals 的內部活動</h2>
<p>在其他消息中，首席執行官 Michael A. Metzger 於 9 月 8 日星期一出售了 157,307 股 Syndax Pharmaceuticals 的股票。該股票以平均價格 16.41 美元出售，總交易額為 2,581,407.87 美元。出售後，首席執行官直接持有該公司 298,661 股股票，價值約 4,901,027.01 美元。此次交易使其持股減少了 34.50%。該出售在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。內部人士持有該公司 4.10% 的股票。</p>
<h2>Syndax Pharmaceuticals 的價格表現</h2>
<p>NASDAQ:SNDX 的股票在星期一開盤價為 20.12 美元。該公司的市值為 17.5 億美元，市盈率為 -5.17，貝塔值為 0.73。該公司的流動比率為 4.71，速動比率為 4.55，債務與股本比率為 2.06。Syndax Pharmaceuticals, Inc. 的 1 年最低價為 8.58 美元，1 年最高價為 20.20 美元。該公司的 50 日移動平均線為 15.85 美元，200 日移動平均線為 13.26 美元。</p>
<p>Syndax Pharmaceuticals (NASDAQ:SNDX - 獲取免費報告) 最近於 11 月 3 日發佈了其財報。該公司報告本季度每股收益為（0.70）美元，超過了市場共識預期的（0.74）美元，超出幅度為 0.04 美元。Syndax Pharmaceuticals 的股本回報率為 -130.47%，淨利潤率為 -428.48%。該公司本季度的收入為 4587 萬美元，而分析師預期為 4908 萬美元。去年同期，該公司每股收益為（0.98）美元。與去年同期相比，Syndax Pharmaceuticals 的季度收入增長了 266.4%。賣方分析師預測 Syndax Pharmaceuticals, Inc. 本年度每股收益將為 -3.72 美元。</p>
<h2>分析師評級升級與降級</h2>
<p>幾家研究機構最近對 SNDX 進行了評估。Weiss Ratings 在 11 月 25 日的研究報告中重新發布了對 Syndax Pharmaceuticals 的 &#34;賣出（d-）&#34; 評級。B. Riley 在 8 月 6 日的研究報告中將 Syndax Pharmaceuticals 的評級提升至 &#34;強力買入&#34;。巴克萊在 11 月 24 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 22.00 美元提高至 35.00 美元，並給予該公司 &#34;增持&#34; 評級。花旗集團在 8 月 5 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 46.00 美元提高至 51.00 美元，並給予該股票 &#34;買入&#34; 評級。最後，高盛集團在 9 月 5 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 20.00 美元提高至 24.00 美元，並給予該公司 &#34;買入&#34; 評級。一位分析師對該股票給予了強力買入評級，九位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;適度買入&#34;，共識目標價為 37.20 美元。</p>
<p><strong>閲讀我們最新的 SNDX 股票報告</strong></p>
<h2>關於 Syndax Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的小分子抑制劑，針對 KMT2A 重排的急性白血病和實體腫瘤的 menin-MLL 結合相互作用；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Syndax Pharmaceuticals</li>
<li>Roth IRA 計算器：計算您的潛在回報</li>
<li>擔心通貨膨脹？這三隻 ETF 提供真正的保護</li>
<li>最佳航空航天股票投資</li>
<li>英特爾的黑色星期五突破：蘋果傳聞推動假日反彈</li>
<li>為什麼理解期權交易量對成功的期權交易至關重要</li>
<li>Klarna 的加密計劃：解決其盈利問題的計劃</li>
</ul>
<p><strong>想看看其他對 SNDX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
<p>在考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Syndax Pharmaceuticals 並不在名單上。</p>
<p>雖然 Syndax Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Syndax制藥

<p>Geode Capital Management LLC 在第二季度將其在 Syndax Pharmaceuticals 的持股增加了 1.3%，目前持有 2,049,350 股，價值 1920 萬美元。其他機構投資者也調整了他們的持股。Syndax 的首席執行官出售了部分股份，公司報告第三季度收入同比增長 266.4%。分析師對該股票給予了 “適度買入” 的共識評級，目標價格為 37.20 美元</p>

<p>Geode Capital Management LLC boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 1.3% in the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 2,049,350 shares of the company's stock after purchasing an additional 26,365 shares during the quarter. Geode Capital Management LLC owned about 2.38% of Syndax Pharmaceuticals worth $19,195,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Geode Capital Management LLC 在最近向證券交易委員會的披露中表示，在第二季度增持了 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免費報告) 的股份，增幅為 1.3%。該公司在本季度額外購買了 26,365 股後，持有 2,049,350 股該公司的股票。Geode Capital Management LLC 在最近一個季度末持有 Syndax Pharmaceuticals 約 2.38% 的股份，價值 19,195,000 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><p>Other institutional investors also recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter worth $179,000. XTX Topco Ltd bought a new position in Syndax Pharmaceuticals in the 1st quarter worth $783,000. Deutsche Bank AG lifted its position in Syndax Pharmaceuticals by 127.7% during the 1st quarter. Deutsche Bank AG now owns 204,732 shares of the company's stock worth $2,516,000 after acquiring an additional 114,828 shares during the last quarter. Invesco Ltd. boosted its holdings in Syndax Pharmaceuticals by 49.7% during the first quarter. Invesco Ltd. now owns 76,848 shares of the company's stock valued at $944,000 after acquiring an additional 25,524 shares during the period. Finally, Aigen Investment Management LP bought a new stake in Syndax Pharmaceuticals during the first quarter valued at about $297,000.</p>
<div class="lb-trans"><p>其他機構投資者最近也調整了對該公司的持股。Universal Beteiligungs und Servicegesellschaft mbH 在第一季度新購入了 Syndax Pharmaceuticals 的股份，價值 179,000 美元。XTX Topco Ltd 在第一季度購買了 Syndax Pharmaceuticals 的新頭寸，價值 783,000 美元。德意志銀行在第一季度將其在 Syndax Pharmaceuticals 的持股增加了 127.7%。德意志銀行目前持有 204,732 股該公司的股票，價值 2,516,000 美元，此前在上個季度額外購入了 114,828 股。Invesco Ltd. 在第一季度將其在 Syndax Pharmaceuticals 的持股增加了 49.7%。Invesco Ltd. 目前持有 76,848 股該公司的股票，價值 944,000 美元，此前在此期間額外購入了 25,524 股。最後，Aigen Investment Management LP 在第一季度新購入了價值約 297,000 美元的 Syndax Pharmaceuticals 的股份。</p>
</div><h2>Insider Activity at Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 的內部活動</h2>
</div><p>In other news, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the sale, the chief executive officer directly owned 298,661 shares in the company, valued at approximately $4,901,027.01. The trade was a 34.50% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Michael A. Metzger 於 9 月 8 日星期一出售了 157,307 股 Syndax Pharmaceuticals 的股票。該股票以平均價格 16.41 美元出售，總交易額為 2,581,407.87 美元。出售後，首席執行官直接持有該公司 298,661 股股票，價值約 4,901,027.01 美元。此次交易使其持股減少了 34.50%。該出售在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。內部人士持有該公司 4.10% 的股票。</p>
</div><h2>Syndax Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 的價格表現</h2>
</div><p>Shares of NASDAQ:SNDX opened at $20.12 on Monday. The firm has a market capitalization of $1.75 billion, a PE ratio of -5.17 and a beta of 0.73. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $20.20. The business's 50 day moving average is $15.85 and its 200-day moving average is $13.26.</p>
<div class="lb-trans"><p>NASDAQ:SNDX 的股票在星期一開盤價為 20.12 美元。該公司的市值為 17.5 億美元，市盈率為 -5.17，貝塔值為 0.73。該公司的流動比率為 4.71，速動比率為 4.55，債務與股本比率為 2.06。Syndax Pharmaceuticals, Inc. 的 1 年最低價為 8.58 美元，1 年最高價為 20.20 美元。該公司的 50 日移動平均線為 15.85 美元，200 日移動平均線為 13.26 美元。</p>
</div><p>Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, November 3rd. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.04. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The firm had revenue of $45.87 million during the quarter, compared to analysts' expectations of $49.08 million. During the same period last year, the business earned ($0.98) earnings per share. Syndax Pharmaceuticals's quarterly revenue was up 266.4% compared to the same quarter last year. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals (NASDAQ:SNDX - 獲取免費報告) 最近於 11 月 3 日發佈了其財報。該公司報告本季度每股收益為（0.70）美元，超過了市場共識預期的（0.74）美元，超出幅度為 0.04 美元。Syndax Pharmaceuticals 的股本回報率為 -130.47%，淨利潤率為 -428.48%。該公司本季度的收入為 4587 萬美元，而分析師預期為 4908 萬美元。去年同期，該公司每股收益為（0.98）美元。與去年同期相比，Syndax Pharmaceuticals 的季度收入增長了 266.4%。賣方分析師預測 Syndax Pharmaceuticals, Inc. 本年度每股收益將為 -3.72 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>Several research firms recently weighed in on SNDX. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Syndax Pharmaceuticals in a research report on Tuesday, November 25th. B. Riley raised Syndax Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Wednesday, August 6th. Barclays increased their price objective on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, November 24th. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, August 5th. Finally, The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $37.20.</p>
<div class="lb-trans"><p>幾家研究機構最近對 SNDX 進行了評估。Weiss Ratings 在 11 月 25 日的研究報告中重新發布了對 Syndax Pharmaceuticals 的 &#34;賣出（d-）&#34; 評級。B. Riley 在 8 月 6 日的研究報告中將 Syndax Pharmaceuticals 的評級提升至 &#34;強力買入&#34;。巴克萊在 11 月 24 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 22.00 美元提高至 35.00 美元，並給予該公司 &#34;增持&#34; 評級。花旗集團在 8 月 5 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 46.00 美元提高至 51.00 美元，並給予該股票 &#34;買入&#34; 評級。最後，高盛集團在 9 月 5 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 20.00 美元提高至 24.00 美元，並給予該公司 &#34;買入&#34; 評級。一位分析師對該股票給予了強力買入評級，九位給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;適度買入&#34;，共識目標價為 37.20 美元。</p>
</div><p><strong>Read Our Latest Stock Report on SNDX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 SNDX 股票報告</strong></p>
</div><h2>About Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Syndax Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的小分子抑制劑，針對 KMT2A 重排的急性白血病和實體腫瘤的 menin-MLL 結合相互作用；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Worried About Inflation? These 3 ETFs Offer Real Protection</li>
<li>Best Aerospace Stocks Investing</li>
<li>Intel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>Klarna's Crypto Play: A Plan to Fix Its Profit Problem</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Syndax Pharmaceuticals</li>
<li>Roth IRA 計算器：計算您的潛在回報</li>
<li>擔心通貨膨脹？這三隻 ETF 提供真正的保護</li>
<li>最佳航空航天股票投資</li>
<li>英特爾的黑色星期五突破：蘋果傳聞推動假日反彈</li>
<li>為什麼理解期權交易量對成功的期權交易至關重要</li>
<li>Klarna 的加密計劃：解決其盈利問題的計劃</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SNDX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 SNDX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05EWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Syndax Pharmaceuticals 並不在名單上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Syndax Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Geode Capital Management LLC 在 Syndax 製藥公司$SNDX 中持有 1920 萬美元的頭寸